Table 1. Budget impact in 5 years concerning the treatment of HPTS in CKD in the dialysis population using vitamin D analogues with the expansion of paricalcitol use (DAF setting).
| Year | Eligible population | Budgetary impact with oral calcitriol * (Base scenario) | Diffusion rate for paricalcitol | Budgetary impact with paricalcitol ** and calcitriol * (proposed scenario) | Incremental budgetary impact with paricalcitol |
|---|---|---|---|---|---|
| 2021 | 27.363 | R$ 73.574.279,71 | 12% | R$ 77.702.845,36 | R$ 4.128.565,65 |
| 2022 | 25.539 | R$77.253.526,08 | 14% | R$ 85.165.059,46 | R$ 7.911.533,38 |
| 2023 | 23.464 | R$ 81.116.202,38 | 16% | R$ 93.178.647,48 | R$ 12.062.445,10 |
| 2024 | 21.118 | R$ 85.171.988,30 | 18% | R$ 101.780.652,73 | R$ 16.608.663,43 |
| 2025 | 18.478 | R$ 89.430.563,52 | 20% | R$ 111.009.911,04 | R$ 21.579.347,52 |
| Total in 5 years | R$ 406.546.560,00 | - | R$ 468.837.115,73 | R$ 62.290.555,73 |
*
Annual cost of treatment with oral calcitriol per patient = R$ 1260,32;
**
Annual cost of treatment with paricalcitol, per patient = R$ 2,574.00.
DAF: pharmacy assistance department; CKD: chronic kidney disease; SHPT: second hyperparathyroidism.